CandlesenseCandlesense
News/Companies/ELUT

ELUT News

Elutia Selected to Exhibit EluPro™ Antibiotic Eluting BioEnvelope at Vizient Innovative Technology Exchange

ELUT

(NASDAQ:ELUT) GAITHERSBURG, Md., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today announced that it has been selected to exhibit the EluPro™ Antibiotic-Eluting BioEnvelope at the Vizient Innovative Technology Exchange (“Vizient”). Vizient®, the nation’s largest provider-driven healthcare performance improvement company, will hold the Innovative Technology Exchange on Wednesday, September 17, 2025 in Las Vegas.

September 4, 2025Products
Read more →

Elutia to Participate in Upcoming Investor Conferences

ELUT

GAITHERSBURG, Md., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia”), a pioneer in drug-eluting biomatrix technologies, today announced that Dr. Randy Mills, President and Chief Executive Officer, and Matt Ferguson, Chief Financial Officer, will participate in the following upcoming investor conferences in New York:

August 27, 2025Conference
Read more →

Elutia Publishes Peer-Reviewed Article Describing First Validated Method For Measuring Antibiotic Release From Biologic Envelope

ELUT

May 28, 2025
Read more →

Lake Street Maintains Buy on Elutia, Lowers Price Target to $8

ELUT

May 9, 2025
Read more →

Elutia Q1 EPS $(0.21) Misses $(0.20) Estimate, Sales $6.03M Miss $6.65M Estimate

ELUT

May 8, 2025
Read more →

Elutia Initiates EluPro Registry Study To Collect Patient Outcome Data

ELUT

April 21, 2025
Read more →

Elutia Confirms That The Ongoing Global Tariff Environment Has Had No Material Impact On Its Commercial Or Operational Performance.

ELUT

April 14, 2025
Read more →

Elutia To Debut Its EluPro Antibiotic-Eluting BioEnvelope At HRS Annual Meeting

ELUT

April 2, 2025
Read more →

Elutia Enters Into An Agreement With Advantus Health Partners To Provide Access Of Elutia's Elupro Antibiotic Eluting Bioenvelope To Advantus' Core Group Purchasing Organizations Solutions Portfolio; Terms Not Disclosed

ELUT

March 27, 2025
Read more →

Elutia Announces Publication Of New Preclinical Data On Antibiotic-Eluting Biologic Envelope

ELUT

March 25, 2025
Read more →

Cantor Fitzgerald Reiterates Overweight on Elutia, Maintains $8 Price Target

ELUT

March 7, 2025
Read more →

Elutia Q4 GAAP EPS $(0.26) Misses $(0.25) Estimate, Sales $5.47M Miss $5.90M Estimate

ELUT

March 6, 2025
Read more →

Cantor Fitzgerald Reiterates Overweight on Elutia, Maintains $10 Price Target

ELUT

November 15, 2024
Read more →

Elutia Q3 2024 GAAP EPS $0.03 Beats $(0.44) Estimate, Sales $5.922M Miss $6.600M Estimate

ELUT

November 14, 2024
Read more →